Loading clinical trials...

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo

NCT03100058•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. informed consent
•2. (BMI\>=30) or (BMI\>=27 with history of CV disease, hypertension, dyslipidemia, pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)
•3. willing to comply with life-style intervention and treatment during the full duration of the study (approximately 54 weeks)

Exclusion Criteria

•Hypersensitivity to any of the study medications
•Pregnancy or lactating women
•History of malignancies
•Use of pharmacologically active weight loss products
•Bariatric surgery
•Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening visit.
•HbA1c \>10% at the screening visit.

Locations (83)

Novartis Investigative Site

Anniston, Alabama, United States

Novartis Investigative Site

Jasper, Alabama, United States

Novartis Investigative Site

Beverly Hills, California, United States

Novartis Investigative Site

Carmichael, California, United States

Novartis Investigative Site

Concord, California, United States

Novartis Investigative Site

Los Angeles, California, United States

Novartis Investigative Site

Northridge, California, United States

Novartis Investigative Site

Roseville, California, United States

Novartis Investigative Site

San Ramon, California, United States

Novartis Investigative Site

Stockton, California, United States

Key Dates

Start Date

May 6, 2017

Primary Completion Date

March 2, 2018

Completion Date

August 2, 2018

Last Updated

February 6, 2020

Enrollment

460

ACTUAL participants

Conditions

ObesityOverweight

Interventions

LIK066

DRUG

Placebo

DRUG

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss